Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150486 | 0.90 | AR (0.50) | ARPGR | |
| SCHEMBL4160315 | 0.89 | AR (0.48) | ARPGRRXRARXRBRXRG | |
| SCHEMBL4149313 | 0.89 | AR (0.48) | ARPGRRXRARXRBRXRG | |
| SCHEMBL4151762 | 0.89 | AR (0.48) | ARPGRRXRARXRBRXRG | |
| SCHEMBL4145871 | 0.88 | AR (0.48) | ARPGRRXRARXRBRXRG | |
| SCHEMBL13777356 | 0.88 | AR (0.47) | ARPGRRXRARXRBRXRG | |
| SCHEMBL4154134 | 0.87 | AR (0.53) | ARPGRRXRARXRBRXRG | |
| SCHEMBL4156909 | 0.87 | AR (0.56) | ARPGR | |
| SCHEMBL4149787 | 0.87 | AR (0.53) | ARPGR | |
| SCHEMBL4151676 | 0.85 | AR (0.48) | ARPGRRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | claimed |
| EP-1888512-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | claimed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1888512-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885RXRA 50/4885 |
| US-20090170907-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | AR 4/4885PGR 27/4885RXRA 244/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885RXRA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.